Our Expertise

ISO accredited assays

We provide ISO 15189-accredited assays to assess outcomes of early phase clinical trials.

Guided screening of vaccine/therapeutic candidates

We generate deep data to guide down-selection of vaccine/therapeutic candidates to avoid late-stage failures.

Translational research solutions

We support bench to bedside translation of infectious disease therapeutics and vaccines in a timely and affordable manner.

Proposed design of our trials: We analyse deep data, such as transcriptomics, metabolomics and proteomics, to study correlates of adverse events and immunogenicity. Together with analysis of humoral and cellular responses we are able to build a network of information pertaining to the performance of vaccine or therapeutic interventions. (Image created with BioRender.com)

Notable Clinical Trials

• NCT04906980 – Janssen Research & Development, LLC
  Safety, Tolerability and Pharmacokinetics of a DENV Inhibitor in Participants With Confirmed Dengue Fever.
• NCT04490857 – Arcturus Therapeutics
  Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects.
• NCT04429529 – Tychan Pte Ltd
  Safety of TY027, a Treatment for COVID-19, in Adults.
• NCT03746015 – Takeda Vaccines
  Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults.
• NCT03776786 – Tychan Pte Ltd
  Safety and Tolerability of an Antibody Against Yellow Fever Virus (TY014) in Adults.
• NCT04728347 – Arcturus Therapeutics
  Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021.
• NCT01943305 – Investigator initiated trial
  The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Adults.
• NCT04267809 – Investigator initiated trial
  Modulating Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection.
  　
  For more information on our expertise and services, click here.